While PD-1 and PD-L1 blocking antibodies enhance the activity of cytotoxic T lymphocytes (CD8+ T cells) in peripheral tissues and inside tumours, CTLA-4-blocking antibodies activate CD8+ T cells and suppress the activity of Tregs in the initial T cell activation stage [16,17]. This evidence concerns the gene CTLA4 and neoplasm.